The economics of benign prostatic hyperplasia and lower urinary tract symptoms in the United States

被引：99
作者：
Taub D.A. [1 ]
Wei J.T. [1 ]
机构：
[1] Department of Urology, Taubman Health Care Center, University of Michigan Health System, Ann Arbor, MI 48109-0330
来源：
Current Urology Reports | 2006年 / 7卷 / 4期
关键词：
Benign Prostatic Hyperplasia; Lower Urinary Tract Symptom; Health Care Expenditure; Transurethral Resection; Tamsulosin;
D O I：
10.1007/s11934-996-0006-0
中图分类号：
学科分类号：
摘要：
Throughout the past several decades, interest in health care economics has increased as health care spending has soared-currently in excess of 1.5 trillion dollars and comprising approximately 16% of the nation's Gross Domestic Product. Benign prostatic hyperplasia (BPH) and its associated clinical manifestation of lower urinary tract symptoms is one of the most common medical conditions of aging men. BPH has been, and continues to be, a major factor in health care expenditures in the United States, costing up to 4 billion dollars each year. During the past 15 years, considerable changes in the patterns of care for BPH patients have evolved, resulting in similarly profound economic alterations. In this article, we examine contemporary trends in practice patterns for BPH and their associated impact on the cost of care for this condition. Copyright © 2006 by Current Science Inc.
引用
收藏
页码：272 / 281
页数：9
相关论文
共 80 条
[1]  
Platz E.A., Smit E., Curhan G.C., Et al., Prevalence of and racial/ethnic variation in lower urinary tract symptoms and noncancer prostate surgery in U.S. men, Urology, 59, pp. 877-883, (2002)
[2]  
Weis K.A., Epstein R.S., Huse D.M., Et al., The costs of prostatectomy for benign prostatic hyperplasia, Prostate, 22, pp. 325-334, (1993)
[3]  
Saigal C.S., Joyce G., Economic costs of benign prostatic hyperplasia in the private sector, J Urol, 173, pp. 1309-1313, (2005)
[4]  
By the numbers, health care economics, Modern Healthcare, SUPPL., pp. 2-38, (2003)
[5]  
Anderson G.F., Hussey P.S., Frogner B.K., Waters H.R., Health spending in the United States and the rest of the industrialized world, Health Affairs, 24, pp. 903-914, (2005)
[6]  
Heffler S., Smith S., Keehan S., Et al., Health spending projections through 2013, Health Affairs Suppl Web Exclusives, W4, pp. 79-93, (2004)
[7]  
Woolhandler S., Campbell T., Himmelstein D.U., Costs of health care administration in the United States and Canada, N Engl J Med, 349, pp. 768-775, (2003)
[8]  
McConnell J.D., Barry M.J., Bruskewitz R.C., Et al., Benign Prostatic Hyperplasia: Diagnosis and Treatment. Clinical Practice Guideline, 8, (1994)
[9]  
Goluboff E.T., Olsson C.A., Urologists on a tightrope: Coping with a changing economy, J Urol, 151, pp. 1-4, (1994)
[10]  
Wei J.T., Calhoun E., Jacobsen S.J., Urologic diseases in America project: Benign prostatic hyperplasia, J Urol, 173, pp. 1256-1261, (2005)
12345678